Marseille, France–(BUSINESS WIRE)–Regulatory news:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate“or the”Company”) announced the results of the vote of its shareholders during the Annual General Meeting (“AGM”), which was held on May 20, 2022 in Marseille. All resolutions were passed in accordance with the recommendations of the Management Board.
A total of 134 votes were cast out of a total of 32,598,725 shares giving right to 33,088,040 voting rights, representing a quorum of 40.88%.
The resolutions, voting results and other documents relating to the AGM as well as the registration of the AGM will be available in the 2022 Annual General Meeting section of the Company’s website.
The Company’s 2021 20-F is available in the Investors section of the website.
As part of the resolutions voted by the shareholders, Dr Sally Bennett was appointed as a new member of the Supervisory Board. She was appointed member of the Audit Committee at the Supervisory Board meeting of May 20, 2022.
“We are very pleased to welcome Dr Sally Bennett as a new member of the Supervisory Board of Innate Pharma”, mentioned Hervé Brailly, Chairman of the Supervisory Board of Innate Pharma. “His deep experience in finance and his in-depth knowledge of the healthcare and capital markets will be an asset to the Company. As Innate continues to execute its strategy, we are committed to regularly evolving the composition of our Board of Directors to ensure that we have the right mix of skills and experience to advance our goals and reflect the various views of Innate’s shareholders.
Dr. Sally Bennett has over 20 years of experience in financial analysis and financial markets in the life sciences and biopharmaceutical industry. She is currently a senior member of the private investment team (part-time) at HealthCor, a large US healthcare-focused investment firm, where she previously managed the public biopharmaceutical investment portfolio and currently co-leads the more recent movement of funds towards private investment. She is a member of the Institute of Directors (IoD) and has obtained the CertIoD qualification. Dr Bennett holds a BSc in Anatomy and an MD, both with Honours, from the University of Manchester.
Today, Mr. Patrick Langlois has decided to resign from his mandate as a member of the Supervisory Board of Innate Pharma.
“Patrick has been a valued member of the Supervisory Board and we are grateful to him for his significant contribution over the past twelve years. On behalf of the Supervisory Board, I would like to thank him for his commitment over the years and wish him well luck for the future,” mentioned Herve Brailly.
To date, the Supervisory Board of Innate Pharma is composed of:
- Hervé Brailly, President
- Irina Staatz-Granzer, Vice President
- Sally Bennet
- Jean-Yves Blay
- Pascale Boissel
- Gilles Brisson
- Veronique Chabernaud
- Bpifrance Participations, represented by Olivier Martinez
About Innate Pharma:
Innate Pharma SA is a clinical-stage oncology-focused global biotechnology company dedicated to improving treatments and clinical outcomes for patients through antibody therapeutics that harness the immune system to fight cancer.
Innate Pharma’s large antibody portfolio includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in understanding natural killer cell biology and has expanded its expertise in tumor microenvironment and tumor antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry, including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-product collaboration with AstraZeneca.
Based in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.
Learn more about Innate Pharma at www.innate-pharma.com.
Information on Innate Pharma shares:
Euronext: IPH Nasdaq: IPHA
Disclaimer of forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. , is intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among others, uncertainties inherent in research and development, including those relating to the safety, progress and results of its ongoing and planned clinical trials and preclinical studies, the review and regulatory approval of its product candidates, the company’s commercialization efforts, the company’s continued ability to raise capital to fund its development, and the overall impact of the COVID-19 outbreak on the global healthcare system and the company’s business, financial condition and results of operations. For a further discussion of risks and uncertainties that could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors section. (“Risk Factors”) of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF’s website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31 2021, and subsequent filings and reports filed with the AMF or the SEC, or otherwise made public, by the Company.
This press release and the information it contains do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares of Innate Pharma in any country whatsoever.